# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER</th>
</tr>
</thead>
</table>

## KIDNEY CANCER — PART IV

### IMMUNOTHERAPY/TUMOR VACCINES

**Adoptive Immunotherapy**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphokine-activated Killer (LAK) Cells</td>
<td>1022</td>
</tr>
<tr>
<td>Tumor-infiltrating Lymphocytes (TILs)</td>
<td>1022</td>
</tr>
<tr>
<td>Tumor-Sensitized Lymph Node Cells</td>
<td>1023</td>
</tr>
<tr>
<td>Autolymphocyte Therapy (ALT)</td>
<td>1023</td>
</tr>
<tr>
<td>Dendritic Cells (DC)</td>
<td>1023</td>
</tr>
</tbody>
</table>

### Active Specific Immunotherapy

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous Tumor Vaccines</td>
<td>1024</td>
</tr>
<tr>
<td>Autologous Tumor-Derived Heat Shock Protein-Peptide Complex-96 (HSPPC) Vaccine</td>
<td>1024</td>
</tr>
<tr>
<td>Tumor-Specific, Mutated, von Hippel-Lindau Peptides</td>
<td>1024</td>
</tr>
<tr>
<td>CD40 Ligand (CD40L)</td>
<td>1025</td>
</tr>
</tbody>
</table>

## LUNG CANCER — PART I

### ETIOLOGY AND GLOBAL EPIDEMIOLOGY

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Epidemiology</td>
<td>1041</td>
</tr>
<tr>
<td>Triad Epidemiology</td>
<td>1042</td>
</tr>
<tr>
<td>Lung Cancer in the USA</td>
<td>1042</td>
</tr>
<tr>
<td>Lung Cancer in Europe</td>
<td>1042</td>
</tr>
<tr>
<td>Lung Cancer in Japan</td>
<td>1042</td>
</tr>
<tr>
<td>Etiology</td>
<td>1043</td>
</tr>
<tr>
<td>Tobacco Smoking</td>
<td>1043</td>
</tr>
<tr>
<td>Environmental Factors</td>
<td>1045</td>
</tr>
<tr>
<td>Hereditary Factors</td>
<td>1045</td>
</tr>
</tbody>
</table>

## LUNG CANCER — PART II

### SCREENING, DIAGNOSIS, AND CLASSIFICATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung Cancer Screening</td>
<td>1074</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>1076</td>
</tr>
<tr>
<td>Low-dose Helical Computed Tomography (CT)</td>
<td>1076</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>1078</td>
</tr>
<tr>
<td>Breath Analysis</td>
<td>1079</td>
</tr>
<tr>
<td>Molecular Markers</td>
<td>1079</td>
</tr>
<tr>
<td>Presentation and Diagnosis</td>
<td>1080</td>
</tr>
<tr>
<td>Brush Cytology</td>
<td>1080</td>
</tr>
<tr>
<td>Endoscopy/Bronchoscopy</td>
<td>1080</td>
</tr>
<tr>
<td>Biopsy</td>
<td>1083</td>
</tr>
<tr>
<td>Computed tomography (CT)</td>
<td>1083</td>
</tr>
<tr>
<td>Nuclear medicine</td>
<td>1083</td>
</tr>
<tr>
<td>Histology and Classification</td>
<td>1084</td>
</tr>
</tbody>
</table>

## LUNG CANCER — PART III

### SMALL CELL LUNG CANCER—EPIDEMIOLOGY, TUMOR MARKERS, STAGING, PROGNOSIS, DISEASE MONITORING, AND CURRENT TREATMENT STRATEGIES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>1105</td>
</tr>
<tr>
<td>Tumor Markers</td>
<td>1106</td>
</tr>
<tr>
<td>Oncogenes and Tumor suppressor genes</td>
<td>1106</td>
</tr>
<tr>
<td>Neuroendocrine Markers</td>
<td>1106</td>
</tr>
<tr>
<td>Diagnosis, Staging, Prognosis, Disease Monitoring</td>
<td>1106</td>
</tr>
<tr>
<td>Serum Markers</td>
<td>1107</td>
</tr>
<tr>
<td>Neuron-specific enolase</td>
<td>1108</td>
</tr>
<tr>
<td>Pro-gastrin-releasing peptide</td>
<td>1108</td>
</tr>
<tr>
<td>Chromogranin A</td>
<td>1108</td>
</tr>
<tr>
<td>Multiple serum markers</td>
<td>1108</td>
</tr>
<tr>
<td>Angiogenesis Markers</td>
<td>1109</td>
</tr>
<tr>
<td>Detection of Tumor Cells in Bone Marrow</td>
<td>1111</td>
</tr>
<tr>
<td>Noninvasive Imaging</td>
<td>1112</td>
</tr>
<tr>
<td>Bone Scans</td>
<td>1112</td>
</tr>
<tr>
<td>Scintigraphy</td>
<td>1112</td>
</tr>
</tbody>
</table>

## MANAGEMENT OF REFRACTORY/RELAPSED SCLC

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Resistance in SCLC</td>
<td>1126</td>
</tr>
<tr>
<td>Second-line Chemotherapy</td>
<td>1127</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>1127</td>
</tr>
<tr>
<td>Topotecan</td>
<td>1127</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>1127</td>
</tr>
</tbody>
</table>

## LUNG CANCER — PART IV

### NON-SMALL-CELL LUNG CANCER—EPIDEMIOLOGY, TUMOR MARKERS, DIAGNOSIS, STAGING, AND PROGNOSIS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>1129</td>
</tr>
<tr>
<td>Gender Variations in the Incidence of NSCLC</td>
<td>1129</td>
</tr>
<tr>
<td>Age Factors in the Incidence of NSCLC</td>
<td>1131</td>
</tr>
<tr>
<td>Stage at Diagnosis</td>
<td>1131</td>
</tr>
<tr>
<td>Survival</td>
<td>1131</td>
</tr>
<tr>
<td>NSCLC Incidence by Histologic Type</td>
<td>1131</td>
</tr>
<tr>
<td>Tumor Markers</td>
<td>1133</td>
</tr>
<tr>
<td>Hereditary Factors</td>
<td>1133</td>
</tr>
<tr>
<td>Other Biomarkers</td>
<td>1135</td>
</tr>
<tr>
<td>Diagnosis and Screening</td>
<td>1135</td>
</tr>
<tr>
<td>Noninvasive Imaging</td>
<td>1135</td>
</tr>
<tr>
<td>Electron beam tomography (EBT)</td>
<td>1135</td>
</tr>
</tbody>
</table>
Positron emission tomography (PET) 1135

In vitro Approaches 1135

Cell-associated transferrin receptor (TfR) 1135
Cyto 21-1 1135
DR-70 1136
Gastrin-releasing protein receptor (GRPR) 1136
Heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 1136
Homeobox (HOX) genes 1141
MAb 28K29 1142
Micrometastases detection 1142
Microsatellite alterations 1142
Telomerase 1142

STAGING 1143

Revisions in the International System for Staging Lung Cancer 1143
Noninvasive Imaging 1143
CT staging 1143
FDG PET imaging 1143
MR imaging 1144
Surgical Staging 1144
Mediastinoscopy 1144
Intra-operative sentinel lymph node mapping 1144
Molecular Substaging 1145

PROGNOSIS 1146

Serum Markers 1146
Tissue Pathology 1147
Angiogenesis evaluation 1147
Genetic Tests 1147
FDG PET Imaging 1148

LUNG CANCER — PART V
NON-SMALL-CELL LUNG CANCER — CURRENT MANAGEMENT STRATEGIES

Epidemiology by Age and Stage in the USA 1150
Incidence of NSCLC by Gender and Age 1150
Incidence of NSCLC by Stage 1150
First-year and Five-year Survival by Stage 1150
Treatment Approaches by Stage 1150
Surgery 1150

Curative Surgery 1150
Minimally invasive surgery 1151
Video-assisted thoracic surgery (VATS) 1152
Surgery in Lung Metastases 1152

RADIOTHERAPY (RT) 1153
External Beam Radiotherapy 1153
Intensity Modulated Radiation Therapy (IMRT) 1155
Brachytherapy 1155
Intraluminal brachytherapy 1155
Intraoperative brachytherapy 1155
Proton-beam Radiotherapy 1156

CHEMOTHERAPY 1156
Types of Chemotherapy in NSCLC 1164
Single-agent chemotherapy 1164
Combination chemotherapy 1164
High-dose chemotherapy 1166
Novel Chemotherapeutics Approved for the Treatment of NSCLC 1166

BIOLGIC AGENTS 1166
Interleukin 2 (IL-2) 1166
Interferon β (IFN-β) 1166

MULTIMODALITY THERAPY 1167
Adjuvant Chemotherapy 1167
Chromoradiotherapy 1168
Neoadjuvant/Induction Chemotherapy and Trimodality Therapy 1168

OTHER TREATMENT MODALITIES 1181
Laser Ablation 1181
Photodynamic Therapy (PDT) 1181
Photofrin 1182
LumaCare LC-051 1183
PH-10 1183
Hyperthermia 1183
BSDL2000/3D System 1184
Perfusion-induced systemic hyperthermia (PISH) 1184
Cryotherapy 1184
Radiofrequency bronchoscopic surgery with cryotherapy 1184
Stents 1185
Silicone stents 1185
Expandable metallic stents 1185

LUNG CANCER — PART VI
NOVEL AGENTS/FORMULATIONS IN DEVELOPMENT

NOVEL CHEMOTHERAPEUTICS 1190
Spindle Poisons 1191
Anhydrovinblastine 1191
BMS-184476 1191
Maytansinoid immunoconjugates 1191
PG-TXL 1192
Taxoprexin 1192
T67 1192
Topoisomerase I Inhibitors 1192
Exatecan mesylate 1192
TAS-103 1192
XR5000 1193
Antifolates 1193
Almitra 1193
S-1 1193
Nucleosides 1193
Decitabine 1193
FMTC 1193
Platinum-based Agents 1202
Nedaplatin 1202
Oxaliplatin 1203
Satraplatin 1203
Other Agents 1203
Bendamustine 1203
CHS 828 1203
CI-994 1204
Irinotecan 1204
Temozolomide 1204
Tirapazamine 1204

NOVEL FORMULATIONS AND DRUG DELIVERY APPROACHES 1205
Lipid Formulations 1205
Onco TCS 1205
Liposome-encapsulated paclitaxel 1205
Aerosol Delivery 1205
Aerosol doxorubicin 1206
Aerosol retinoids 1206
Aerosolized GM-CSF 1206
Inhaled RFS 2000 1206

ANGIOGENESIS INHIBITORS 1206
Matrix Metalloproteinase Inhibitors (MMPI) 1206
BMS-275291 1207
Marimastat 1207
Necrostat 1207
Prinomastat 1208
Angiostatin and Endostatin 1208
Squalamine 1208
**REGULATION**

- Cell Cycle Regulation
  - Flavopiridol
  - UCN-01
- Approaches Targeting the Epidermal Growth Factor Receptor (EGFr)
  - ABX-EGF
  - Trastuzumab
  - ZD 1839
- Farnesyl Transferase Inhibitors (FTI)
  - BN-50730
  - ZD 1839
- Approaches Targeting Other Markers
  - rAd/p53
  - RPR/INGN 201
  - ONYX-015

**IMMUNOTHERAPY/VACCINES**

- Cytokine-producing Tumor Vaccines
  - SRL172
- Vaccines Against CEA-expressing Tumors
  - Anti-CEA antibodies
  - Recombinant viruses expressing CEA protein or peptides
  - Dendritic cells expressing CEA
- Vaccines Against Ganglioside-expressing Tumors
  - Fucosyl-GM1-keyhole limpet hemocyanin (KLH) conjugate vaccine
  - Mitumomab (BEC2)
- Vaccines Against MUC-1-expressing Tumors
  - BLP-25
- Vaccines Against Tumors Expressing HER2
  - HER2 Peptide Vaccine

**RADIATION THERAPY**

- Radioimmunoconjugates

**OTHER AGENTS**

- Angiodyne
- rhuMAb-VEGF
- Semoxind
- BN-50730

**TESTING APPROACHES**

- Urine cytology/cytopathology
- ImmunoCyt
- Quanticyt
- BCLA-4
- Fibrin/fibrinogen degradation products (FDP)

**IMMUNE MARKERS**

- Telomerase
- p53 mutations and other genetic markers
- Cytokeratin (CK)
- Hyaluronic acid (HA) and hyaluronidase (HAase)
- Cystoscopy/Biopsy

**HISTOPATHOLOGY AND BLADDER CANCER TYPES**

- Transitional Cell Carcinoma (TCC)
- Squamous Cell Carcinoma
- Adenocarcinoma

**STAGE AND GRADE**

**ANTICANCER DRUGS AND MARKETS**

**UPDATE ON TAXANES**

**COMMERCIAL PRODUCTS**

- Taxol
- Taxotere

**CLINICAL INDICATIONS**

- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Other Cancer Indications

**THE OUTLOOK FOR TAXOL AND ITS COMPETITION**

- Taxane Sources and Production Processes
  - Aphios
  - Cytoceonal Pharmaceuticals
  - Dabur India
  - NaPro BioTherapeutics
  - Phytogen Life Sciences
  - Phyton
  - Samyang Genex
  - Xecem International
  - Generic Paclitaxel

**FUTURE ONCOLOGY VOLUME 5, NUMBER 1-12 INDEX SEPTEMBER 2000**

**COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.**

**FUTURE ONCOLOGY VOLUME 5, NUMBER 1-12 INDEX SEPTEMBER 2000**

**ANTICANCER DRUGS AND MARKETS**

**UPDATE ON TAXANES**

**COMMERCIAL PRODUCTS**

- Taxol
- Taxotere

**CLINICAL INDICATIONS**

- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Other Cancer Indications

**THE OUTLOOK FOR TAXOL AND ITS COMPETITION**

- Taxane Sources and Production Processes
  - Aphios
  - Cytoceonal Pharmaceuticals
  - Dabur India
  - NaPro BioTherapeutics
  - Phytogen Life Sciences
  - Phyton
  - Samyang Genex
  - Xecem International
  - Generic Paclitaxel

**FUTURE ONCOLOGY VOLUME 5, NUMBER 1-12 INDEX SEPTEMBER 2000**

**COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.**
CELL THERAPEUTICS

EnzyMed 1033
Guilford Pharmaceutical 1033
MacroMed 1033
Matrix Pharmaceutical 1034
NeoPharm 1034
Phytogen Life Sciences 1034
Pharmacia & Upjohn 1034
Protarga 1034
SuperGen 1035
STS Particles/Medisperse 1035
Xechem International 1035

Novel Taxanes and Analogs 1036

Aventis 1036
Bristol-Myers Squibb 1036
British Technology Group (BTG) 1036
Indena 1036
The Lipsome Company (TLC) 1037
Taxolog 1037
Xechem International 1037

Next Generation of Tubulin Stabilizing Drugs/Spindle Poisons 1037

Apramycin 1037
D-24851 1037
Discodermolide 1038
Eleutherobin 1038
Epothilones 1038
Halimide 1038
LY355703 1038
Lautimalide and isolaunimalide 1039
T138067 1039

SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS ONCOLOGY THERAPEUTICS — PART II

Types of Synthetic Nucleic Acid Constructs in Development as Oncology Therapeutics 1269

Antisense Oligos 1269
Triplex-Forming ODN (TFO) 1269
Catalytic Nucleic Acids/Ribozymes 1270
Hammerhead ribozymes 1271
Minizyme 1271
Maxizymes 1271
Hairpin ribozymes 1271
Snorbozymes 1272
Decoy ribozymes or DNA enzymes (DNAzymes) 1272
Dy-Tex ribozyme analogs 1272
Chimeric Nucleotides 1272

Intracellularly Produced Antisense RNA and DNA 1273
Aptamers 1274
Aptazymes 1275
Aptamers as diagnostics 1276

BIological ACTIVITY OF ODN 1276
CpG-containing ODN 1276
G-rich ODN 1277

ODN Conjugated to Radioisotopes 1278

CLINICAL CONSIDERATIONS 1278

Toxicity 1278
Administration Route 1278
Oral delivery 1278
Pulmonary delivery 1279
Combination Therapy 1279

Starburst polyamidoamine (PAMAM) dendrimers 1241
Copolymer 1245
Amphiphiles 1245
Porphyris 1246
Carrier-ligand conjugates 1246
Controlled-released carriers 1247
Virosomes 1247

ONCOLOGY TRENDS
PRODUCT MARKETS — PART I

PLATINUM-BASED ANTICANCER AGENTS 1046
Cisplatin 1046
Carboplatin 1047
Oxaliplatin 1047

TOPOISOMERASE I INHIBITORS 1048
Topotecan 1049
Irinotecan 1050

THYMIDYLATE SYNTHASE INHIBITORS/ANTIFOLATES AND RELATED AGENTS 1050
Capecitabine 1051
Raltitrexed 1051
UFT 1051

ONCOLOGY TRENDS
PRODUCT MARKETS — PART II

HORMONE MODULATING DRUGS 1084
Antiestrogens 1085
Tamoxifen 1085
Raloxifene 1085
Toremifene 1086
Aromatase Inhibitors 1086
Anastrozole 1087
Exemestane 1088
Fadrozole 1088
Formestane 1089
Letrozole 1089
Antiandrogens 1089
Bicalutamide 1090
Cyproterone acetate 1090
Flutamide 1090
Goserelin 1090
Leuprolide acetate 1091
Nilutamide 1091

OTHER CHEMOTHERAPEUTICS 1091
Alitretinoin 1091
Anthracyclines 1092
Daunorubicin 1092
Epirubicin 1092
Liposomal daunorubicin 1092
Liposomal doxorubicin 1092
Mitoxantrone 1094
Valrubicin 1094
Busulfan 1094
Carmustine Wafer 1094
Etoposide Phosphate 1095
Flutarabine 1095
Gemcitabine 1095
Liposomal Cytarabine 1095
Methoxsalen 1096
Porfimer Sodium 1096
Temozolomide 1096

BIOLOGICALS 1098
Aldesleukin 1098
Denileukin Diftitox 1098
Interferon α 1099

Interferon α-2a 1099
Interferon α-2b 1099
Rituximab 1099
Trastuzumab 1101

ADJUNCT THERAPIES 1101
Amifostine 1101
Colony Stimulating Factors 1102
Filgrastim 1102
Lenograstim 1102
Sargramostim 1102
Oprelvekin 1103
Pamidronate Disodium 1104

MEETING COVERAGE

CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC)
FROM THE 35TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, ATLANTA, GA; MAY 15-18, 1999

APPROACHES TO MAXIMIZE THE ROLE OF CHEMOTHERAPY IN NSCLC 1052
Postoperative Adjunct Chemotherapy in Resected Disease 1053
Neoadjuvant Chemotherapy in Resectable Disease 1053

LIST OF EXHIBITS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Historic and Forecast Taxane Sales in the USA and Abroad</td>
<td>XXXX</td>
</tr>
<tr>
<td>Estimated Cases under Treatment with Taxol and Taxotere Worldwide (1997-1999)</td>
<td>XXXX</td>
</tr>
<tr>
<td>Competitive Strategies in the Paclitaxel Market</td>
<td>XXXX</td>
</tr>
<tr>
<td>Estimated Incidence of Lung Cancer Around the World by Gender in 1999</td>
<td>1043</td>
</tr>
<tr>
<td>Estimated Mortality of Lung Cancer Around the World by Gender in 1999</td>
<td>1044</td>
</tr>
<tr>
<td>Lung Cancer Incidence in Europe by Country and Gender in 1999</td>
<td>1047</td>
</tr>
<tr>
<td>Lung Cancer Deaths by Gender in Europe by Country in 1999</td>
<td>1048</td>
</tr>
<tr>
<td>Lung Cancer Incidence and Deaths in the Triad in 1999</td>
<td>1053</td>
</tr>
<tr>
<td>Global Sales of Selected Anticancer Drugs and Related Products</td>
<td>1054</td>
</tr>
<tr>
<td>Select Platinum-based Drugs in Development</td>
<td>1057</td>
</tr>
<tr>
<td>Selected Topoisomerase I (Topo I) Inhibitors in Development</td>
<td>1062</td>
</tr>
<tr>
<td>Selected Thymidylate Synthase Inhibitors and Related Agents in Development</td>
<td>1068</td>
</tr>
<tr>
<td>Estimated Number of Smokers over 18 Years-of-Age in the USA in 1999 by Gender and Age</td>
<td>1076</td>
</tr>
<tr>
<td>Estimated Number of Smokers by Average Cigarettes Smoked per Day in the USA in 1999 by Gender and Age</td>
<td>1079</td>
</tr>
<tr>
<td>Projects Funded by the NCI Early Detection Research Network</td>
<td>1081</td>
</tr>
<tr>
<td>Epidemiology of Lung Cancer in the USA by Type in 1999</td>
<td>1087</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiestrogen Drugs in Development</td>
<td>1097</td>
</tr>
<tr>
<td>Adverse Cardiac Events with Herceptin</td>
<td>1102</td>
</tr>
<tr>
<td>Incidence and 5-year Survival Estimates of Patients with Small-Cell Lung Cancer in the USA</td>
<td>1107</td>
</tr>
<tr>
<td>Estimated Incidence of Small-Cell Lung Cancer in the Triad in 1999</td>
<td>1109</td>
</tr>
<tr>
<td>Selected Tumor Markers Associated with Small-Cell Lung Cancer</td>
<td>1110</td>
</tr>
<tr>
<td>Standard treatment Options for Small-Cell Lung Cancer</td>
<td>1115</td>
</tr>
<tr>
<td>Estimated Small-Cell Lung Cancer Cases by Type of Treatment in the USA in 1999</td>
<td>1117</td>
</tr>
<tr>
<td>Combination and Multimodality Clinical Trials in Small-cell Lung Cancer</td>
<td>1119</td>
</tr>
<tr>
<td>Histologic Classification of NSCLC and Estimated Incidence in the USA in 2000</td>
<td>1132</td>
</tr>
<tr>
<td>INDEX OF COMPANIES &amp; INSTITUTIONS</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Title</strong></td>
<td><strong>Page</strong></td>
</tr>
<tr>
<td>Staging of NSCLC</td>
<td>1134</td>
</tr>
<tr>
<td>Biomarkers Associated with NSCLC</td>
<td>1137</td>
</tr>
<tr>
<td>Estimated Incidence of NSCLC by Gender and Age</td>
<td>1151</td>
</tr>
<tr>
<td>Estimated Stage Distribution at Diagnosis and 1-year and 5-year Survival of NSCLC Patients by Stage in the USA in 2000</td>
<td>1153</td>
</tr>
<tr>
<td>First-line Treatment of NSCLC by Stage in 2000</td>
<td>1154</td>
</tr>
<tr>
<td>Treatment Options and Prognosis by Stage</td>
<td>1157</td>
</tr>
<tr>
<td>Novel Chemotherapeutics Approved in the USA for the Treatment of NSCLC</td>
<td>1159</td>
</tr>
<tr>
<td>Phase II and III Combination and Multimodality Clinical Trials in NSCLC</td>
<td>1169</td>
</tr>
<tr>
<td>Potential Numbers of Chemotherapy Regimens for the Treatment of Lung Cancer</td>
<td>1192</td>
</tr>
<tr>
<td>Selected Agents in Development for the Treatment of Lung Cancer</td>
<td>1194</td>
</tr>
<tr>
<td>Estimated Incidence of Bladder Cancer Around the World by Region and Gender in 2000</td>
<td>1231</td>
</tr>
<tr>
<td>Estimated Mortality of Bladder Cancer Around the World by Region and Gender in 2000</td>
<td>1232</td>
</tr>
<tr>
<td>Estimated Bladder Cancer Incidence in Europe by Country and Gender in 2000</td>
<td>1234</td>
</tr>
<tr>
<td>Estimated Bladder Cancer Mortality in Europe by Country and Gender in 2000</td>
<td>1235</td>
</tr>
<tr>
<td>Estimated Incidence of Bladder Cancer by Age Group in the USA in 2000</td>
<td>1236</td>
</tr>
<tr>
<td>Estimated Mortality of Bladder Cancer by Age Group in the USA in 2000</td>
<td>1238</td>
</tr>
<tr>
<td>Markers Associated with Bladder Cancer</td>
<td>1242</td>
</tr>
<tr>
<td>In Vitro Tests for the Screening, Diagnosis, and Monitoring of Bladder Cancer</td>
<td>1251</td>
</tr>
<tr>
<td>Comparison of BTA Stat and Cytology in Bladder Cancer Monitoring</td>
<td>1258</td>
</tr>
<tr>
<td>Comparisons of UBC, BTA and NMP-22 Tests</td>
<td>1268</td>
</tr>
<tr>
<td>Incidence of Bladder Cancer by Histologic Type in the USA in 2000</td>
<td>1271</td>
</tr>
<tr>
<td>Basis for Staging of Bladder Cancer</td>
<td>1273</td>
</tr>
<tr>
<td>Incidence of Bladder Cancer by Stage in the USA in 2000</td>
<td>1275</td>
</tr>
<tr>
<td>Incidence of Bladder Cancer by Grade in the USA in 2000</td>
<td>1277</td>
</tr>
</tbody>
</table>

**INFORMATION**

12 de Octubre Hospital 1123
Abbott Laboratories 1029, 1032, 1080, 1089, 1091, 1194, 1199, 1200, 1201
Abgenix 1194, 1210
Academisch Ziekenhuis der Vrije Universiteit 1119
Access Pharmaceuticals 1057
AccuMed International 1078, 1079
Addenbrookes NHS Trust 1264
ADL (Germany) 1259
Advanced Bio science Lab 1081
Aeterna Laboratories 1194, 1207
Agouron Pharmaceuticals 1068, 1069, 1194, 1208
Akademiska Hospital 1146
Akorn 1183
Albert Einstein Cancer Center 1166, 1215
Albert Einstein College of Medicine 1272
Aleoa 1253
Allermex 1247
Allegheny General Hospital 1052, 1156
Allegheny University 1034
Allos Therapeutics 1194, 1220
Almirall Prodesfarma 1094
Altarex 1194
Alza 1032, 1054, 1055, 1057, 1089, 1092, 1101, 1123, 1159, 1241
Ambion 1252
AMDL 1136
American Home Products (AHP) 1031, 1055, 1097, 1194
American Pharmaceutical Partners (APP) 1046
Amgen 1055, 1089, 1090, 1102, 1120
Amgen-Kirin 1055, 1102
Amrad 1102
AnorMED 1057, 1194
Ams CANCER Center 1120
Ansan 1201
Anthra Pharmaceuticals 1094
Antigenics 1024
Antisoma 1194
Aphios 1029
Aquilia Biopharmaceuticals 1200, 1217
Areturus Engineering 1082
Armand-Frappier Institute 1245
Aronex Pharmaceuticals 1057, 1194
Arthur G. James CANCER Hospital & Richard J. Solove Research Institute 1206, 1220
Asahi Chemical Industry 1142
Asta Medica 1037, 1046, 1118, 1200, 1211
AstraZeneca 1051, 1054, 1055, 1057, 1068, 1085, 1087, 1088, 1090, 1097, 1193, 1194
Atairgin Technologies 1081
Auckland CANCER Research Laboratory 1063, 1193, 1202
Auckland Hospital 1123
Avax Technologies 1062
Aventis 1025, 1026, 1036, 1037, 1049, 1118, 1054, 1055, 1160, 1091, 1095, 1102, 1194, 1197, 1198, 1209, 1222
Aventis Pasteur 1201, 1215
AVI BioPharma 1236
Axcen Pharma 1162
Azienda Ospedaliera San Luigi Gonzaga 1184
Baker Norton Pharmaceuticals 1031, 1032
Banyu 1062
BarD Diagnostic Sciences 1257
Bar-Ilan Research and Development 1201
Barr Laboratories 1054, 1083, 1085
Battelle Pulmonary Therapeutics 1194, 1206
Bayer 1081, 1096, 1206, 1252
Bayer Diagnostics 1141
Baylor College of Medicine 1206, 1253, 1274
Beaufour Ipsen 1194, 1209
Beekman Coulter 1197, 1219
Bedford Laboratories 1046, 1092
Beijing Tumor Institute 1259
Belki Diagnostics 1109, 1252
Berlex Laboratories 1054, 1095
Bethany Medical Center 1165
Betticher Institute of Medical Oncology 1102
BICO 1184
BioChem Pharma 1195
Biocontrol Technology 1184
BioInvent International 1194
Biomab 1062
Biomira 1195, 1217
Bion 1251
Bion Diagnostics 1252, 1257
BioNumerik Pharmaceuticals 1062, 1068, 1195
BioStratum 1195
BioGenex 1167
Bio-Techology General 1029
Boehringer Ingelheim 1031, 1200
Boehringer Mannheim 1055, 1057, 1109
Boston Medical Center 1259
Boston Scientific 1185
Brandford University 1097
Bristol-Myers Squibb 1025, 1026, 1027, 1028, 1029, 1030, 1032, 1036, 1037, 1038, 1046, 1047, 1051, 1054, 1057, 1093, 1095, 1101, 1117, 1118, 1122, 1161, 1163, 1191, 1192, 1193, 1195, 1196, 1200, 1201, 1203, 1207
HemoCleanse 1184
Herbert Irving Comprehensive Cancer Center 1166
Hoag Cancer Center 1024, 1157
Hoechst Celanese 1199
Hoffmann-La Roche 1050, 1054, 1055, 1057, 1069, 1089, 1109, 1101, 1102, 1194, 1197
Hood Laboratories 1185
Hôpital Arnaud de Villeneuve 1119
Hôpital Ste-Marguerite 1121
Hospital Arnaud de Villanova 1179
Hospital de Cruces 1173
Hospital del Mar 1180
Hospital Duran i Reynals 1113, 1114, 1173
Hospital Großhansdorf 1122
Hospital Gauting 1122
Hospital Hallwag-Klinik 1120
Hospital Hopital Ste-Marguerite 1121
Hubei Medical University 1136
Humboldt-Universität zu Berlin 1271
Hybridon 1233
Hybritech 1259
Hydro Med Sciences 1089
Hygeia Hospital 1174
Hyseq 1138, 1197
IBC Pharmaceuticals 1197, 1239
IGC Pharmaceuticals 1099
IDC Pharmaceuticals 1049, 1054, 1099, 1100
IDL Biotech 1146, 1251, 1265
IIT 1184
IGT Pharma 1191, 1197
Ilex Oncology 1063, 1068, 1196, 1197, 1207
Imatron 1135
ImClone Systems 1197, 1217
Immune Response 1246
Immunix 1025, 1031, 1032, 1054, 1055, 1094, 1103, 1194, 1201, 1210
Immunod-Derived Molecules (IDM) 1199
ImmunoGen 1191, 1197, 1198
Immunomedics 1197, 1219
Immunotech 1219
Imperial Cancer Research Fund (ICRF) 1062, 1194, 1195, 1199, 1201
Imperial Cancer Research Technology (ICRT) 1199, 1201
Incyte Genomics 1198
Indena 1036
Indiana University 1089, 1173, 1174
Inex Pharmaceuticals 1062, 1198
Inova 1029
Innovir Laboratories 1241
Inselspital 1171
INSERM 1130, 1240
Institut de Genetique Moléculaire de Montpellier 1238
Institut Curie 1036
Institut Henri Beaufour 1062
Institute for Drug Development, Cancer Therapy and Research Center 1036
Institute of Biostructure 1183
Institute of Cancer Research 1198
Institute of Pathology, Berlin 1135
International Agency for Research on Cancer 1130, 1227
Intracel 1252
Introgen Therapeutics 1198, 1212
ISIS Innovation 1057
Ish Pharmaceuticals 1198, 1213, 1233, 1236, 1246
Istituto Nazionale di Ricerca sul Cancro 1164
Istituto Nazionale di Ricerca sul Cancro 1164
Istituto Nazionale Tumori 1142, 1179
Ivax 1029, 1031, 1032
Janssen 1088
Janssen Biotech 1035, 1057, 1201
Janssen Pharmaceutica 1198
Japan Tobacco 1194, 1195
Johann Wolfgang Goethe Universität 1245
Johns Hopkins University 1033, 1034, 1074, 1081, 1192, 1195, 1197
Johnson & Johnson 1054, 1055, 1185, 1211
Johnson & Johnson Research 1239
Johnson Matthey 1057, 1203
Jonsson Comprehensive Cancer Center 1210
Josai University 1269
Kagoshima University 1069
Kaiser Foundation Hospitals 1209, 1228
Kaplan Cancer Center 1211
Karmanos Cancer Institute 1141
Karlo 1097
Karolinska Institute 1237
Kav Kendall Leukaemia Fund 1198
Kellogg Cancer Center 1144
Kent Cancer Centre 1214
Kimeragen 1273
Kinki University School of Medicine 1171
Klinke Pharma 1097, 1102, 1200, 1203
Kline Pharmaceuticals 1097
Klinikum Grosshadern (Germany) 1135, 1184
Kliniken Ilbenbüren 1120
Konica 1259
Kosan Biosciences 1038
KSBiomedix 1214
Kurume University School of Medicine 1178
Kyomed 1097
Kyowa Hakko Kogyo 1068, 1198, 1200, 1210
Lachensa 1030
Lemery 1032
Leo Pharmaceutical Products 1198, 1203
Leukaemia Research Fund 1198
LeXigen Pharmaceuticals 1198
Lexon 1142, 1252
Ligand Pharmaceuticals 1091, 1092, 1097, 1098
The Liposome Company 1037, 1055, 1093
Lithuanian Oncology Center 1167
Loma Linda University Medical Center 1156, 1220
Lombardi Cancer Center 1081
Louisiana Oncology Associates 1172
Louisiana State University Health Sciences Center 1263
Lueca Hospital 1173
Ludwig-Maximilians Universisty 1135
LumaCare 1183
Lungenklinik 1155
Lynx Therapeutics 1233
MacroMed 1030, 1033
Mallinckrodt 1212
Magainin Pharmaceuticals 1198, 1208
Marie Lannelongue Hospital 1151
Martek Biosciences 1200
Massachusetts General Hospital 1181, 1246, 1259, 1275
Massachusetts Institute of Technology 1033, 1181, 1246, 1252, 1259
Matriech 1243, 1252, 1258, 1259
Matrix Pharmaceutical 1034, 1057, 1062, 1193, 1198
Maxia Pharmaceuticals 1198
Maxim Pharmaceuticals 1195
Mayo Clinic 1045, 1074, 1102, 1157, 1160, 1183, 1206, 1209, 1211
Mayo Graduate School of Medicine 1254
MBG Technologies 1183
M. D. Anderson Cancer Center (MDACC) 1024, 1033, 1035, 1057, 1062, 1137, 1139, 1082, 1194, 1195, 1198, 1202, 1206, 1207, 1208, 1209, 1211, 1240, 1249, 1250, 1259
MDS Research Foundation 1037
Medarex 1199
Medeva 1094
Medical Research Council (MRC) 1168
MedImmune Oncology 1159
Medisperse 1035
Memorial-Sloan Kettering Cancer Center 1074, 1172, 1176, 1197, 1199, 1200, 1206, 1217
Menssana Research 1079
Mentor 1252, 1261
Merek 1062, 1097, 1221
Merek RGA 1197, 1199, 1217, 1256
Metaxas Memorial Cancer Hospital 1159, 1180
MGI Pharma 1055, 1199, 1204
Michigan Molecular Institute 1244
Microsolvie 1185
Middlesex Hospital-Meyerstein Institute 1119
Milveron Medical Technologies 1182
Moffitt Cancer Center 1141
Montana State University 1029
Mount Sinai Comprehensive Cancer Center 1176
Mount Sinai School of Medicine 1024, 1082
MPI Research 1068
Munich University of Medicine 1024, 1033, 1035, 1057, 1062, 1137, 1139, 1082, 1194
Muro Pharmaceuticals 1198
Mycotax Pharmaceuticals 1195
Mylan Pharmaceutical 1029, 1032, 1085
Shionogi 1057, 1200, 1202
Sicor 1032, 1057
Sicor de Mexico 1032
Sydney Kimmel Cancer Center 1198
Siemens Medical Systems 1184
Sigmal Pharmaceuticals 1097
SkyPharma 1095, 1096
SmithKline Beecham 1049, 1055, 1093, 1097, 1100, 1118, 1122, 1124, 1165
Southern Arizona VA HealthCare System 1205
Southern Research Institute 1196, 1199, 1200
Southwest Oncology Group (SWOG) 1163
Sparta Pharmaceuticals 1035, 1069, 1098
Spectral Imaging 1081
SR Pharma 1200
SRI International 1063
St. Luke's Medical Center 1023
Stanford University 1213
Stehlin Foundation for Cancer Research 1049, 1063, 1201
STS Particles 1035
Suigen 1200, 1209
Sumitomo 1201
Sun Hill Glucose 1030
SUNY 1036
SuperGen 1032, 1035, 1049, 1057, 1063, 1069, 1098, 1193, 1201, 1206
Supratek Pharma 1245
Syren Pharmaceuticals 1057
Taiho Pharmaceutical 1063, 1069, 1097, 1192, 1193, 1195, 1200, 1201
Takara Shuzo 1214, 1218
Takeda Chemical Industries 1055, 1091, 1191, 1197, 1198
Tampere University Hospital 1151, 1257
Tanabe Seiyaku Hospital 1171
Tienfau Hospital 1171
Titan Pharmaceuticals 1201
Tokushima Bunri University 1247
Transgene 1195, 1201
Triangle Pharmaceuticals 1202
Truman VA Hospital 1132
Tularik 1039, 1192, 1201
Ultrapharm Chemicals 1097
Unimod Pharmaceuticals 1035, 1055
Unita Operativa di Oncologia Medica 1170
Unitech 1058
Universita Cattolica del Sacro Cuore 1178
Universita degli Studi 1146, 1153
Université de Montréal 1272
University College London 1118, 1200
University Hospital, Groningen 1124, 1177
University Hospital Nijmegen (The Netherlands) 1251
University Medical Center Nijmegen (The Netherlands) 1255, 1256
University Hospital, Rotterdam 1222
University Hospital, Yugoslavia 1169
University Hospitals, Münster and Greifswald 1120
University of Alabama at Birmingham 1233, 1277
University of Alberta 1241
University of Arizona Cancer Center 1205, 1208
University of Basel (Switzerland) 1263
University of Bern 1247
University of Berne 1123
University of British Columbia 1197, 1241
University of California 1194, 1199, 1200, 1202, 1206
University of California Davis Cancer Center 1210
University of California San Diego Cancer Center 1197, 1198
University of California, Los Angeles (UCLA) 1113, 1209
University of Cambridge 1264
University of Chicago Cancer Research Center 1165, 1192, 1203, 1212
University of Cincinnati 1159
University of Colorado 1081, 1200, 1209, 1270, 1275
University of Copenhagen 1236, 1237
University of Delaware 1273
University of Florida 1123, 1197
University of Gatzemeier 1122
University of Iowa 1033
University of Kentucky 1063, 1201
University of London, School of Pharmacy 1057
University of Louisville School of Medicine 1182
University of Mainz 1166
University of Maryland 1081, 1142, 1238
University of Massachusetts 1272, 1278
University of Medicine and Dentistry of New Jersey (UMDNJ) 1269
University of Miami School of Medicine 1266
University of Michigan 1033, 1081, 1244, 1275
University of Milan 1147
University of Minnesota School of Medicine 1147
University of Missouri 1132
University of Montreal 1193
University of North Carolina 1245, 1246
University of Ottawa 1207
University of Padua 1115
University of Pennsylvania 1039, 1058, 1183
University of Pennsylvania Health System’s Institute for Human Gene Therapy 1246
University of Pittsburgh 1023, 1063, 1082, 1121, 1130, 1162, 1196, 1242, 1252, 1260
University of South Florida 1081
University of Texas 1033, 1035, 1194, 1195, 1196, 1198, 1199, 1202, 1240
University of Texas at Austin 1272
University of Texas Medical Branch 1184
University of Texas Southwestern Medical Center 1082
University of Tsukuba 1271
University of Vienna 1176, 1255
University of Virginia Health Sciences Center 1268
University of Washington 1082, 1196, 1218
University of Wisconsin Comprehensive Cancer Center 1162, 1208
University of York 1097
University Medical School of Pecs 1144
Upplands University 1146
UroCor 1252
U.S. Bioscience 1046, 1055, 1101, 1121
Uath State University 1039
VA Northern CA Health Care System 1120, 1210
Valentis 1202
VailGen 1273
Vanderbilt Cancer Center 1052
Vanderbilt University 1053, 1174, 1209, 1220
Veterans Affairs Hospital, Durham 1153, 1176
Veterans’ General Hospital-Taipei 1177
ViaCirQ 1184
Vincent T. Lombardi Cancer Research Center 1215
Vion 1202
Virgen del Rocio Hospital 1123
Virgen de la Victoria Hospital 1123
Virginia Tech 1036
Virogenetics 1215
Viventia Biotech 1202
VivolRx 1037
Vysis 1252, 1263
Wadley Institutes 1196
Walther Cancer Institute 1173
Warner-Lambert 1068, 1069, 1097
Washington State University 1029
Wayne State University 1180
Weil Medical College 1217
West Virginia University 1238
Weston Park Hospital 1120
Whitehead Institute 1195
William Beaumont Hospital 1146
Xechem International 1030, 1035, 1037
Xenova Group 1063, 1193, 1202
Xillix Technologies 1080
Yale Cancer Center 1160
Yale University 1081, 1133, 1202, 1264, 1270, 1275
Yew Tree Pharmaceuticals 1032
York Medical 1202
Zambon Group 1196
Zarix 1069
Zelenka Nursery 1029
Zeneca Diagnostics 1081
Zeneca Pharmaceuticals 1090
Zentralkrankenhausene Sankt-Jürgen-Strasse (Germany) 1167
Zenyaku Kogyo 1099
NEW MEDICINE’S Oncology KnowledgeBASE (nm|OK) is an invaluable internet resource for anyone involved with drug development in the oncology field. NEW MEDICINE has designed a means to keep track of the incredible amount of information generated daily in this field, providing a rationally organized compendium of thousands of pieces of data that can be searched with ease. Information is presented across many variables, logically sequestered to reveal activities in a specific arena of interest. Use of nm|OK is an important resource in the performance of market research/technology assessment studies, in evaluating licensing/collaboration opportunities, in product positioning, and in helping executives place new information impacting their business in context, on a daily basis.

FOUR MODULES OF nm|OK MAY BE NOW ACCESSED ON THE INTERNET INCLUDING:

New and Marketed Drug Module

These modules currently provide detailed information on 2,204 drugs in development, marketed drugs, drug targets, or enabling technologies, for treating cancer and complications associated with this disease and its treatment, such as anemia, cachexia, edema, emesis, hypercalcemia, infection, mucositis, neutropenia, pain, thrombocytopenia, xerostomia, etc. The database can be searched by:
- therapeutic indication (malignancy, pain, emesis, infection, etc.)
- cancer indication (breast, prostate, colorectal, etc.)
- clinical indication (metastatic melanoma, hormone-refractory prostate cancer, limited-stage small-cell lung cancer, etc.)
- clinical status (IND, phase I/II/III/IV, NDA)
- geographical location where trials are taking place
- drug category (taxane, topoisomerase I inhibitor, hormone modulator, etc.)
- drug type (protein/peptide, natural product, etc.)
- technology (immunotherapeutic/vaccine, monoclonal antibody, photodynamic therapy, etc.)
- mechanism (apoptosis enhancer, antiangiogenic, cell cycle modulator, etc.)
- administration route (oral, IV, nasal, intraperitoneal, intralesional, etc.)
- delivery mode (liposomal, electroporation, pumps, implants, etc.)
- primary developer or affiliate for a complete pipeline

Additionally, records incorporate:
- patent information
- price and market size for marketed drugs
- orphan drug status by indication
- description of various enabling technologies that may be used to discover novel cytotoxic/cytostatic, or immunomodulating agents

Company Module

Also, nm|OK profiles 1016 companies/developers describing their cancer-related activities, and presenting oncology pipelines.

Marker Module

This module currently comprises 350 records delineating the role of molecular markers in various malignancies. Records may be searched by marker and/or cancer indication.

PLANNED ADDITIONS TO THE DATABASE

nm|OK is a work in progress. Currently, an Access™-based cancer epidemiology module is in development and will be available in mid 2001. Numerous other modules are also in development, including a database of combination trials.

For more information, or a demo of nm|OK call NEW MEDICINE at 949-830-0448 or visit our web site at oncologyknowledgebase.com.
FUTURE ONCOLOGY:

FUTURE ONCOLOGY (ISSN 1082-331X) is published as 12 issues (several double issues) per year, with a free annual index listing companies/institutions and subjects covered, and a binder.

- YES, I want to order a subscription to FUTURE ONCOLOGY.

Subscription Information:

- One-year subscription is $840 U.S. and $900 abroad; please specify period (from _______ to _______ ). Additional subscriptions sent in the same envelope are $390 each.

Back Issues:

- Volumes V2, V3, V4, and V5 are $2,400 (U.S.) and $2,460 (outside the U.S.).
- Volumes V4 and V5 are $1,400 (U.S.) and $1,460 (outside the U.S.).

Inquiry Information:

- Please send me a sample issue of FUTURE ONCOLOGY
- Please send me the index of Volumes 1, 2, 3, 4 and 5

Oncology Knowledgebase (nm | OK):

- YES, I want to order a order nm | OK.

nm | OK is available by subscription only and access is provided via a password. The annual subscription rate is $2,950 for the first “seat” and $290.00 for each additional seat for up to 5 seats in the same physical location. Subscription rates for company-wide distribution are negotiable, based on physical location/IP designation and number, or users.

Please enter my subscription to nm | OK to start on (date) ___________________________ at $2,950.00 ____________

Additional seats # ____________ at $290.00 each ____________

Total ____________

Inquiry Information:

- Please call me for a walk-through the database and a complimentary pass.

Sale of NEW MEDICINE hard copy and electronic publications is made under the following conditions:

Unauthorized photocopying, distribution or electronic storage is strictly prohibited. Information incorporated in NEW MEDICINE products is developed from various sources believed to be reliable. There can be no assurance that such information is accurate in all respects, however, and the publisher cannot be held liable for errors. Errors, when discovered, will be corrected. Subscriptions may not be canceled, but may be transferred.

All orders must be repaid or accompanied by a signed order form or P.O. #. Subscriptions to FUTURE ONCOLOGY and nm | OK will begin upon receipt of payment. Products are nonreturnable; please, feel free to call for information.

My check for $ _______ is enclosed (make checks payable to NEW MEDICINE, INC.). Payment must accompany your order; checks must be drawn on a U.S. bank

Wire Transfer:

Washington Mutual, 400 East Main Street.
Stockton, CA 95290. 800-374-4646. Routing #321180748.
NEW MEDICINE INC. Account #087900008012618

Credit Card: ☐ Visa ☐ AmEx ☐ M/C Exp. Date: ______

Bill me on P.O. #: ____________________________________________________

Signature: ____________________________________________________________

Name: ________________________________________________________________

Title: ____________________________ Company: ______________________

Address: ______________________________________________________________

City: ____________________________ State: ____________________________

Zip Code: ______________________ Country: ______________________

Telephone: ______________________ Fax: ____________________________

E-mail ________________________________________________________________

Return to: NEW MEDICINE, INC.:

P.O. Box 909 • Lake Forest • CA 92630
Telephone: (949) 830-0448 • Fax: (949) 830-0887
E-mail: info@newmedinc.com
Web Sites: www: newmedinc.com
www.oncologyknowledgebase.com

FUTURE ONCOLOGY Staff:

PUBLISHER AND EDITOR: Katie Siafaca, MS
ASSOCIATE EDITOR: Timothy Sharon, PhD
ASSISTANT EDITOR: Adele Simon
CIRCULATION: Amish Kalyani
DESIGN & PRODUCTION: Jill Burch

EDITORIAL BOARD

BIO TECHNOLOGY & APPLIED SCIENCES:
James W. Hawkins, PhD, Editor, Antisense Research and Development

CLINICAL PRACTICE:
Leonard Sender, MD, Medical Director, Hemtopoietic Stem Cell Program, St. Joseph Hospital Regional Center, Orange, CA

REIMBURSEMENT AND MANAGED CARE:
Elan Rubinstein, PharmD, MPH, Consultant